Anti-TNF-α antibody (infliximab) therapy supports the recovery of enos and VEGFR2 protein expression in endothelial cells

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 2, 2011, Pages 323-335

  Altorjay, I ^a   Vereb Z ^a   Serfozo, Z ^b   Bacskai, I ^a   Batori R ^a   Erdodi, F ^a   Udvardy, M ^a   Sipka, S ^a   Lanyi, A ^a   Rajnavolgyi E ^a   Palatka, Károly ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b BALATON LIMNOLOGICAL RESEARCH INSTITUTE   (Hungary)

Author keywords

Crohn's disease; eNOS; HUVEC; Inflammatory bowel disease; Infliximab; TNF ; Vascular endothelial growth factor receptor 2

Indexed keywords

AZATHIOPRINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INFLIXIMAB; MESALAZINE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR 2; ANGIOGENIN; ANTIINFLAMMATORY AGENT; FIBROBLAST GROWTH FACTOR 2; MONOCLONAL ANTIBODY; NOS3 PROTEIN, HUMAN; PANCREATIC RIBONUCLEASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SERUM; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; BLOOD; CASE CONTROL STUDY; CELL CULTURE; DRUG ANTAGONISM; ENDOTHELIUM CELL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; UPREGULATION; HUMAN CELL CULTURE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELLS, CULTURED; CROHN DISEASE; ENDOTHELIAL CELLS; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; NITRIC OXIDE SYNTHASE TYPE III; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEASE, PANCREATIC; RNA, MESSENGER; SERUM; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 80051733035     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400206     Document Type: Article

References (30)

1. Beisner J, Stange EF, Wehkamp J. Innate antimicrobial immunity in inflammatory bowel diseases. Expert Rev Clin Immunol 2010; 6:809-18.
2. Strober W, Zhang F, Kitani A, Fuss I, Fichtner-Feigl S. Proinflammatory cytokines underlying the inflammation of Crohn's disease. Curr Opin Gastroenterol 2010; 26:310-7.
3. Laroux FS, Grisham MB. Immunological basis of inflammatory bowel disease: role of the microcirculation. Microcirculation 2001; 8:283-301. (Pubitemid 33598134)
4. Danese S, Sans M, De la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006; 130:2060-73. (Pubitemid 43816964)
5. Roifman I, Sun YC, Fedwick JP, Panaccione R, Buret AG, Liu H, Rostom A, Anderson TJ, Beck PL. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009; 7:175-82.
6. Gibson PR. Increased gut permeability in Crohn's disease: is TNF the link? Gut 2004; 53:1724-5. (Pubitemid 39556884)
7. Kuldo JM, Westra J, Asgeirsdóttir SA, Kok RJ, Oosterhuis K, Rots MG, Schouten JP, Limburg PC, Molema G. Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. Am J Physiol Cell Physiol 2005; 289:C1229-39. (Pubitemid 41456839)
8. Viemann D, Goebeler M, Schmid S, Nordhues U, Klimmek K, Sorg C, Roth J. TNF induces distinct gene expression programs in microvascular and macrovascular human endothelial cells. J Leukoc Biol 2006; 80:174-85. (Pubitemid 44835538)
9. Yokoyama M, Hirata K, Kawashima S, Kawahara Y. Regulation of nitric oxide synthase gene expression by cytokines. J Card Fail 1996; 2(S):179-85.
10. Fukumura D Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, Buerk DG, Huang PL, Jain RK. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 2001; 98:2604-9. (Pubitemid 32209529)
11. Lin MI, Sessa WC. Vascular Endothelial growth factor signaling to endothelial nitric oxide synthase. Circ Res 2006; 99:666-8. (Pubitemid 44498299)
12. Hatoumi OA, Binion DG, Otterson MF, Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology 2003; 125:58-69. (Pubitemid 36799107)
13. Palatka K, Serfocombining double acute accentzocombining double acute accent Z, Veréb Z, et al. Changes in the expression and distribution of the inducible and endothelial nitric oxide synthase in mucosal biopsy specimens of inflammatory bowel disease. Scand J Gastroenterol 2005; 40:670-80.
14. Palatka K, Serfocombining double acute accentzocombining double acute accent Z, Veréb Z, et al. Effect of IBD sera on expression of inducible and endothelial nitric oxide synthase in human umbilical vein endothelial cells. World J Gastroenterol 2006; 12:1730-8.
15. Kanazawa S, Tsunoda T, Onuma E, Majima T, Kagiyama M, Kikuchi K. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 2001; 3:822-8. (Pubitemid 32240738)
16. Dimmeler S, Zeiher AM. Nitric-oxide an endothelial survival factor. Cell Death Differ 1999; 6:964-8.
17. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999; 5:119-33.
18. Miheller P, Lakatos PL, Horváth G, et al. Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study. BMC Gastroenterol 2009; 9:66.
19. Danese S, Sans M, Scaldaferri F, Fiocchi C, et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 2006; 176:2617-24. (Pubitemid 43201714)
20. Schinzari FAA, Armuzzi A, De Pascalis B, Mores N, Tesauro M, Melina D, Cardillo C. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease. Clin Pharmacol Ther 2008; 83:70-6.
21. Haraldsen G, Rugtveit J, Kvale D, Scholz T, Muller WA, Hovig T, Brandtzaeg P. Isolation and longterm culture of human intestinal microvascular endothelial cells. Gut 1995; 37:225-34.
22. Franzen B, Duvefelt K, Jonsson C, Engelhardt B, Ottervald J, Wickman M, Yang Y, Schuppe-Koistinen I. Gene and protein expression profiling of human cerebral endothelial cells activated with tumor necrosis factor-alpha. Brain Res Mol Brain Res 2003; 115:130-46. (Pubitemid 36859863)
23. Sanders DSA. Mucosal integrity and barrier function in the pathogenesis of early lesions in Crohn's disease. J Clin Pathol 2005; 58:568-72. (Pubitemid 40814012)
24. Kimura H, Esumi H. Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis Acta Bioch Pol 2003; 50:49-59.
25. Capria A, De Nardo D, Baffetti FR, Barbini U, Violo A, Tondo T, Fontana L. Long-term anti-TNF-alpha treatments reverse the endothelial dysfunction in rheumatoid arthritis: the biological coherence between synovial and endothelial inflammation. Int J Immunopathol Pharmacol 2010; 23:255-62.
26. Rutella S, Fiorino G, Vetrano S, et al. Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease. Am J Gastroenterol 2011; 106:762-70.
27. Martínez-Borra J, López-Larrea C, González S, et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002; 97:2350-6.
28. Yan G, You B, Chen SP, Liao JK, Sun J. Tumor necrosis factor-alpha downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-alpha 1. Circ Res 2008; 103:591-7.
29. Agnoletti L, Curello S, Bachetti T, et al. Serum from patient with severe heart failure downregulates eNOS and is proapoptotic. Role of tumor necrosis factor-alpha. Circulation 1999; 100:1983-91. (Pubitemid 29529291)
30. Giraudo E, Primo L, Audero E, Gerber HP, Koolwijk P, Soker S, Klagsbrun M, Ferrara N, Bussolino F. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem 1998; 273:22128-35. (Pubitemid 28405397)